Johnson & Johnson

SWX:JNJ Stock Report

Market Cap: CHF 494.9b

Johnson & Johnson Valuation

Is JNJ undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Future Cash Flow Value

  • Significantly Below Future Cash Flow Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Future Cash Flow Value

What is the Fair Price of JNJ when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Ultimate guide to DCF valuation for stock investing

Learn how to determine fair value like the best investors in the world.

Below Future Cash Flow Value: JNJ (CHF205.19) is trading below our estimate of future cash flow value (CHF347.05)

Significantly Below Future Cash Flow Value: JNJ is trading below future cash flow value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for JNJ?

Key metric: As JNJ is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for JNJ. This is calculated by dividing JNJ's market cap by their current earnings.
What is JNJ's PE Ratio?
PE Ratio29.6x
EarningsUS$21.04b
Market CapUS$613.02b

Price to Earnings Ratio vs Peers

How does JNJ's PE Ratio compare to its peers?

The above table shows the PE ratio for JNJ vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average43.3x
ROP Roche Holding
20.9x8.05%CHF 270.1b
NOVN Novartis
21.1x9.73%CHF 231.0b
GALD Galderma Group
88.1x23.76%CHF 43.6b
SDZ Sandoz Group
42.9x17.01%CHF 31.7b
JNJ Johnson & Johnson
29.6x8.34%CHF 613.0b

Price-To-Earnings vs Peers: JNJ is good value based on its Price-To-Earnings Ratio (29.6x) compared to the peer average (43.3x).

Historical Price to Earnings Ratio

Historical Price to Earnings Ratio compares a stock's price to its earnings over time. Higher ratios indicate that investors are willing to pay more for the stock.

Fetching historical data

Price to Earnings Ratio vs Industry

How does JNJ's PE Ratio compare vs other companies in the European Pharmaceuticals Industry?

3 CompaniesPrice / EarningsEstimated GrowthMarket Cap
JNJ 29.6xIndustry Avg. 21.7xNo. of Companies10PE020406080100+
3 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: JNJ is expensive based on its Price-To-Earnings Ratio (29.6x) compared to the European Pharmaceuticals industry average (21.7x).

Price to Earnings Ratio vs Fair Ratio

What is JNJ's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

JNJ PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio29.6x
Fair PE Ratio37.8x

Price-To-Earnings vs Fair Ratio: JNJ is good value based on its Price-To-Earnings Ratio (29.6x) compared to the estimated Fair Price-To-Earnings Ratio (37.8x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst JNJ forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCHF 205.19
CHF 208.45
+1.59%
8.79%CHF 230.71CHF 153.81n/a22
Jun ’27CHF 175.53
CHF 198.91
+13.32%
12.01%CHF 224.18CHF 121.92n/a23
May ’27CHF 180.24
CHF 197.24
+9.43%
11.73%CHF 222.70CHF 121.12n/a24
Apr ’27CHF 193.58
CHF 192.76
-0.42%
12.00%CHF 223.88CHF 123.93n/a24
Mar ’27CHF 189.30
CHF 179.22
-5.32%
11.22%CHF 203.73CHF 119.16n/a24
Feb ’27CHF 174.52
CHF 178.27
+2.15%
11.68%CHF 204.85CHF 119.82n/a24
Jan ’27CHF 164.02
CHF 166.48
+1.50%
10.46%CHF 190.15CHF 122.80n/a24
Dec ’26CHF 165.72
CHF 163.01
-1.63%
8.28%CHF 185.11CHF 124.75n/a24
Nov ’26CHF 150.85
CHF 158.72
+5.22%
8.44%CHF 178.96CHF 123.29n/a23
Oct ’26CHF 147.90
CHF 143.75
-2.80%
7.91%CHF 167.16CHF 123.38n/a23
Sep ’26CHF 142.01
CHF 142.49
+0.33%
6.12%CHF 161.37CHF 125.06n/a23
Aug ’26CHF 135.73
CHF 142.08
+4.68%
5.37%CHF 154.33CHF 125.90n/a23
Jul ’26CHF 121.93
CHF 134.06
+9.94%
6.47%CHF 146.59CHF 118.86n/a23
Jun ’26CHF 127.26
CHF 138.87
+9.13%
6.47%CHF 151.85CHF 123.12CHF 175.5323
May ’26CHF 129.39
CHF 141.04
+9.01%
6.04%CHF 153.47CHF 124.44CHF 180.2423
Apr ’26CHF 146.91
CHF 149.44
+1.72%
6.58%CHF 167.94CHF 132.58CHF 193.5821
Mar ’26CHF 147.09
CHF 152.12
+3.42%
6.72%CHF 171.54CHF 135.42CHF 189.3021
Feb ’26CHF 139.06
CHF 152.31
+9.53%
6.83%CHF 171.80CHF 135.63CHF 174.5221
Jan ’26CHF 131.02
CHF 155.50
+18.68%
7.23%CHF 191.83CHF 138.29CHF 164.0223
Dec ’25CHF 138.81
CHF 154.33
+11.18%
7.26%CHF 189.73CHF 136.78CHF 165.7223
Nov ’25CHF 140.05
CHF 150.96
+7.79%
7.32%CHF 186.23CHF 134.26CHF 150.8522
Oct ’25CHF 135.98
CHF 144.98
+6.62%
8.03%CHF 181.94CHF 126.93CHF 147.9022
Sep ’25CHF 139.57
CHF 145.43
+4.20%
7.98%CHF 182.80CHF 127.53CHF 142.0122
Aug ’25CHF 141.95
CHF 151.25
+6.55%
7.97%CHF 190.53CHF 132.93CHF 135.7322
Jul ’25CHF 131.55
CHF 154.26
+17.26%
7.72%CHF 193.14CHF 139.24CHF 121.9322
Jun ’25CHF 132.38
CHF 155.34
+17.34%
7.81%CHF 194.24CHF 140.03CHF 127.2622
CHF 204.39
Fair Value
0.4% overvalued intrinsic discount
22
Number of Analysts

Analyst Forecast: Target price is lower than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/29 07:07
End of Day Share Price 2026/06/29 00:00
Earnings2026/03/29
Annual Earnings2025/12/28

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Johnson & Johnson is covered by 53 analysts. 22 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
David ToungArgus Research Company
Matthew MiksicBarclays
Lee HambrightBernstein